Clinical Trial

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
Protocol Amendment History 3 changes
notable Trial sites expanded: 11 -> 15 locations 2026-07-14
notable Primary completion pushed: 2026-06 -> 2026-09-30 2026-07-14
notable Trial sites expanded: 1 -> 9 locations 2026-06-16
Trial Details
NCT Number NCT07223658
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Hyperlipidemia; Mixed
Enrollment 78 participants
Start Date 2025-12-22
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-13